Repeat controlled human malaria infection of healthy UK adults with blood-stage Plasmodium falciparum : Safety and parasite growth dynamics
Copyright © 2022 Salkeld, Themistocleous, Barrett, Mitton, Rawlinson, Payne, Hou, Khozoee, Edwards, Nielsen, Sandoval, Bach, Nahrendorf, Ramon, Baker, Ramos-Lopez, Folegatti, Quinkert, Ellis, Poulton, Lawrie, Cho, Nugent, Spence, Silk, Draper and Minassian..
In endemic settings it is known that natural malaria immunity is gradually acquired following repeated exposures. Here we sought to assess whether similar acquisition of blood-stage malaria immunity would occur following repeated parasite exposure by controlled human malaria infection (CHMI). We report the findings of repeat homologous blood-stage Plasmodium falciparum (3D7 clone) CHMI studies VAC063C (ClinicalTrials.gov NCT03906474) and VAC063 (ClinicalTrials.gov NCT02927145). In total, 24 healthy, unvaccinated, malaria-naïve UK adult participants underwent primary CHMI followed by drug treatment. Ten of these then underwent secondary CHMI in the same manner, and then six of these underwent a final tertiary CHMI. As with primary CHMI, malaria symptoms were common following secondary and tertiary infection, however, most resolved within a few days of treatment and there were no long term sequelae or serious adverse events related to CHMI. Despite detectable induction and boosting of anti-merozoite serum IgG antibody responses following each round of CHMI, there was no clear evidence of anti-parasite immunity (manifest as reduced parasite growth in vivo) conferred by repeated challenge with the homologous parasite in the majority of volunteers. However, three volunteers showed some variation in parasite growth dynamics in vivo following repeat CHMI that were either modest or short-lived. We also observed no major differences in clinical symptoms or laboratory markers of infection across the primary, secondary and tertiary challenges. However, there was a trend to more severe pyrexia after primary CHMI and the absence of a detectable transaminitis post-treatment following secondary and tertiary infection. We hypothesize that this could represent the initial induction of clinical immunity. Repeat homologous blood-stage CHMI is thus safe and provides a model with the potential to further the understanding of naturally acquired immunity to blood-stage infection in a highly controlled setting.
Clinical Trial Registration: ClinicalTrials.gov, identifier NCT03906474, NCT02927145.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
---|---|
Enthalten in: |
Frontiers in immunology - 13(2022) vom: 16., Seite 984323 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Salkeld, Jo [VerfasserIn] |
---|
Links: |
---|
Themen: |
Clinical Trial |
---|
Anmerkungen: |
Date Completed 09.09.2022 Date Revised 15.09.2022 published: Electronic-eCollection ClinicalTrials.gov: NCT03906474, NCT02927145 Citation Status MEDLINE |
---|
doi: |
10.3389/fimmu.2022.984323 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM345897110 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM345897110 | ||
003 | DE-627 | ||
005 | 20231226205234.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3389/fimmu.2022.984323 |2 doi | |
028 | 5 | 2 | |a pubmed24n1152.xml |
035 | |a (DE-627)NLM345897110 | ||
035 | |a (NLM)36072606 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Salkeld, Jo |e verfasserin |4 aut | |
245 | 1 | 0 | |a Repeat controlled human malaria infection of healthy UK adults with blood-stage Plasmodium falciparum |b Safety and parasite growth dynamics |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 09.09.2022 | ||
500 | |a Date Revised 15.09.2022 | ||
500 | |a published: Electronic-eCollection | ||
500 | |a ClinicalTrials.gov: NCT03906474, NCT02927145 | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2022 Salkeld, Themistocleous, Barrett, Mitton, Rawlinson, Payne, Hou, Khozoee, Edwards, Nielsen, Sandoval, Bach, Nahrendorf, Ramon, Baker, Ramos-Lopez, Folegatti, Quinkert, Ellis, Poulton, Lawrie, Cho, Nugent, Spence, Silk, Draper and Minassian. | ||
520 | |a In endemic settings it is known that natural malaria immunity is gradually acquired following repeated exposures. Here we sought to assess whether similar acquisition of blood-stage malaria immunity would occur following repeated parasite exposure by controlled human malaria infection (CHMI). We report the findings of repeat homologous blood-stage Plasmodium falciparum (3D7 clone) CHMI studies VAC063C (ClinicalTrials.gov NCT03906474) and VAC063 (ClinicalTrials.gov NCT02927145). In total, 24 healthy, unvaccinated, malaria-naïve UK adult participants underwent primary CHMI followed by drug treatment. Ten of these then underwent secondary CHMI in the same manner, and then six of these underwent a final tertiary CHMI. As with primary CHMI, malaria symptoms were common following secondary and tertiary infection, however, most resolved within a few days of treatment and there were no long term sequelae or serious adverse events related to CHMI. Despite detectable induction and boosting of anti-merozoite serum IgG antibody responses following each round of CHMI, there was no clear evidence of anti-parasite immunity (manifest as reduced parasite growth in vivo) conferred by repeated challenge with the homologous parasite in the majority of volunteers. However, three volunteers showed some variation in parasite growth dynamics in vivo following repeat CHMI that were either modest or short-lived. We also observed no major differences in clinical symptoms or laboratory markers of infection across the primary, secondary and tertiary challenges. However, there was a trend to more severe pyrexia after primary CHMI and the absence of a detectable transaminitis post-treatment following secondary and tertiary infection. We hypothesize that this could represent the initial induction of clinical immunity. Repeat homologous blood-stage CHMI is thus safe and provides a model with the potential to further the understanding of naturally acquired immunity to blood-stage infection in a highly controlled setting | ||
520 | |a Clinical Trial Registration: ClinicalTrials.gov, identifier NCT03906474, NCT02927145 | ||
650 | 4 | |a Clinical Trial | |
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a Plasmodium falciparum | |
650 | 4 | |a controlled human malaria infection (CHMI) | |
650 | 4 | |a human challenge model | |
650 | 4 | |a malaria | |
650 | 4 | |a malaria immunology | |
700 | 1 | |a Themistocleous, Yrene |e verfasserin |4 aut | |
700 | 1 | |a Barrett, Jordan R |e verfasserin |4 aut | |
700 | 1 | |a Mitton, Celia H |e verfasserin |4 aut | |
700 | 1 | |a Rawlinson, Thomas A |e verfasserin |4 aut | |
700 | 1 | |a Payne, Ruth O |e verfasserin |4 aut | |
700 | 1 | |a Hou, Mimi M |e verfasserin |4 aut | |
700 | 1 | |a Khozoee, Baktash |e verfasserin |4 aut | |
700 | 1 | |a Edwards, Nick J |e verfasserin |4 aut | |
700 | 1 | |a Nielsen, Carolyn M |e verfasserin |4 aut | |
700 | 1 | |a Sandoval, Diana Muñoz |e verfasserin |4 aut | |
700 | 1 | |a Bach, Florian A |e verfasserin |4 aut | |
700 | 1 | |a Nahrendorf, Wiebke |e verfasserin |4 aut | |
700 | 1 | |a Ramon, Raquel Lopez |e verfasserin |4 aut | |
700 | 1 | |a Baker, Megan |e verfasserin |4 aut | |
700 | 1 | |a Ramos-Lopez, Fernando |e verfasserin |4 aut | |
700 | 1 | |a Folegatti, Pedro M |e verfasserin |4 aut | |
700 | 1 | |a Quinkert, Doris |e verfasserin |4 aut | |
700 | 1 | |a Ellis, Katherine J |e verfasserin |4 aut | |
700 | 1 | |a Poulton, Ian D |e verfasserin |4 aut | |
700 | 1 | |a Lawrie, Alison M |e verfasserin |4 aut | |
700 | 1 | |a Cho, Jee-Sun |e verfasserin |4 aut | |
700 | 1 | |a Nugent, Fay L |e verfasserin |4 aut | |
700 | 1 | |a Spence, Philip J |e verfasserin |4 aut | |
700 | 1 | |a Silk, Sarah E |e verfasserin |4 aut | |
700 | 1 | |a Draper, Simon J |e verfasserin |4 aut | |
700 | 1 | |a Minassian, Angela M |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Frontiers in immunology |d 2010 |g 13(2022) vom: 16., Seite 984323 |w (DE-627)NLM215811453 |x 1664-3224 |7 nnns |
773 | 1 | 8 | |g volume:13 |g year:2022 |g day:16 |g pages:984323 |
856 | 4 | 0 | |u http://dx.doi.org/10.3389/fimmu.2022.984323 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 13 |j 2022 |b 16 |h 984323 |